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The severe acute respiratory syndrome–associated
coronavirus (SARS-CoV) spike protein (S) is a major target
for neutralizing antibodies. Retroviral SARS-CoV S
pseudotypes have been constructed and used to develop
an in vitro microneutralization assay that is both sensitive
and specific for SARS-CoV neutralizing antibodies.
Neutralization titers measured by this assay are highly cor-
related to those measured by an assay using replication-
competent SARS-CoV. No cross-neutralization occurred
with human sera known to contain antibodies to coron-
avirus strains OC43 and 229E. The pseudotype assay was
used to profile neutralizing antibody responses against
SARS-CoV S in sequential serum samples taken from 41
confirmed SARS patients during the 2003 outbreak in Hong
Kong and shows long-lasting immunity in most recovered
patients. The pseudotype assay does not require handling
live SARS virus; it is a useful tool to determine neutralizing
titers during natural infection and the preclinical evaluation
of candidate vaccines.
The coronavirus that causes severe acute respiratorysyndrome (SARS-CoV) is a new human pathogen for
which a vaccine may be urgently required should a new
outbreak occur. Studying the magnitude and longevity of
the neutralizing antibody response during natural infection
will help establish correlates of protection to be generated
by immunization. Humoral immunoglobulin (Ig) G, IgM,
and IgA responses to SARS-CoV have been studied exten-
sively (1–7). However, studies of neutralizing antibody
responses during natural infection have been limited (8,9),
partially because neutralization assays must be performed
at biosafety level 3 or higher.
The SARS-CoV genome encodes 4 structural proteins,
the spike (S), membrane (M), envelope (E), and nucleo-
capsid (N) proteins (10). The S protein is the major surface
antigen of the virus, and the neutralizing antibody response
is primarily directed against this protein. Monoclonal anti-
bodies to the S protein neutralize the virus and have been
mapped (11–14). By vaccinating hamsters with a recombi-
nant parainfluenza virus vector, Buchholz et al. found that
the expression of M, E, or N, in the absence of S, did not
induce a neutralizing antibody response (15). Preclinical
studies of SARS-CoV vaccines provide evidence that gen-
erating a strong neutralizing antibody response to SARS-
CoV S may protect against SARS infection (16–19). 
Retroviral and lentiviral pseudotypes have been
employed in lieu of replication-competent virus to study
neutralizing antibody responses to viral infection (20,21).
Pseudotype viruses encode marker genes and bear foreign
viral envelopes (22). The transfer of marker genes to target
cells depends on the function of the envelope protein; there-
fore, the titer of neutralizing antibodies against the enve-
lope can be measured by a reduction in marker gene
transfer. Lentiviral pseudotypes bearing the SARS-CoV
spike protein were first described by Simmons et al. to
study viral entry (23). Other studies have used SARS-CoV
S pseudotyped viruses for identifying receptors (24), exam-
ining viral tropism (25–27), and measuring neutralizing
antibody responses (18,28–30). Yang et al. constructed
lentiviral pseudotypes harboring S, M, or E proteins and
found that only S supported viral entry into target cells (26).
The aim of this study was to establish a neutralizing
antibody assay using murine leukemia virus (MLV)
pseudotypes bearing the SARS-CoV S envelope,
MLV(SARS), and to profile neutralizing antibody respons-
es to SARS-CoV natural infection during a relatively long
period in a cohort of Hong Kong patients who had recov-
ered from the disease.
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Materials and Methods
Patient Samples
A total of 166 blood samples were obtained from 41
patients (68% female) 11–80 years of age who were admit-
ted to the Prince of Wales Hospital, Hong Kong, from
March to May 2003. All study patients fulfilled the World
Health Organization criteria for having a probable case of
SARS. Samples from 7 of the 41 patients were tested for
SARS-CoV by reverse transcription–polymerase chain
reaction (RT-PCR) in a study previously described (31),
and 4 patients had positive results. Pneumonia developed
in all 41 patients, and 6 required intensive care. None of
these patients died of the infection. For most patients, mul-
tiple samples were obtained at sequential times covering
the acute, convalescent, and recovered phase of the dis-
ease. This study was approved by the Prince of Wales
Hospital local institutional ethics committee.
Plasmids and Cell Lines
Construction of the plasmid pCAGGS-S harboring full-
length SARS-CoV S from the Urbani strain has been
described previously (23). The MLV gag/pol construct,
pCMVi, and the green fluorescent protein (GFP) reporter
construct, pCNCG, have been described (32). Vesicular
stomatitis virus envelope protein (VSV-G) expression vec-
tor pMDG has been described previously (33). HIV con-
structs were used as described (34).
All cell lines were cultured in Dulbecco’s Modified
Eagle Medium (DMEM) with Glutamax and high glucose
(Gibco, Paisley, Scotland, UK), supplemented with 10%
fetal calf serum and penicillin/streptomycin. To make the
quail QT6/ACE2 cell line, the gene encoding the receptor
for SARS-CoV, human angiotensin-converting enzyme 2
(ACE2) (35), was cloned from a human primary kidney
cDNA library (Invitrogen, Paisley, Scotland, UK) using
21-mer primers designed to the start and stop of ACE2,
and subcloned into pcdna3.1+. QT6 cells were transfected
by using lipofectamine 2000 and selected with G418, and
a bulk ACE2-positive, G418-resistant population was
grown.
Viral Vector Production and Infection of Target Cells
Confluent plates of 293T cells were split 1:4 the day
before transfection. Each plate of 293T cells was transfect-
ed with 1 µg gag/pol construct, 1.5 µg of enhanced GFP
reporter construct, and 1.5 µg envelope-expressing con-
struct by using the Fugene-6 transfection reagent (36).
Supernatant was harvested 48 h and 72 h posttransfection,
filtered through 0.45-µm filters, and stored at –80°C. MLV
and HIV vector titer were measured on 293T, TE671, and
QT6/ACE2 cells and are presented as infectious units (IU)
per milliliter. Briefly, cells were infected with vector, and
eGFP titers were determined 72 h later by fluorescence-
activated cell sorter (FACS).
Neutralization Assays
Live Virus
Patient serum samples were heat inactivated at 56°C for
30 min and serially diluted from 1:10 in culture medium.
Fifty PFU of SARS Frankfurt strain were added to the
serum dilution and incubated for 1 h at 37°C. We added
5 + 104 Vero E6 cells per well to the virus and serum mix,
and the mixture was incubated in 96-well plates for 4 days,
after which neutralization was assessed by cytopathic
effect (CPE). The neutralization endpoint was taken as the
last well in which complete neutralization was observed.
Serum samples were assayed in duplicate, and positive
results were confirmed in separate assays.
Pseudotype
Patient serum samples were heat inactivated at 56°C for
30 min, 2-fold serially diluted from 1:10 in culture medi-
um, and mixed with MLV(SARS) virions (≈100 IU) at a
1:1 vol/vol ratio. After incubation at 37°C for 1 h, 100 µL
of each dilution was added to QT6/ACE2 cells seeded at
1 + 104 cells per well in 96-well flat-bottomed tissue cul-
ture plates seeded 24 h previously. GFP-positive cells were
counted 48 h later by fluorescence microscopy.
Neutralizing antibody titers are presented as geometric
mean titers of assays performed in triplicate.
Results
Production of MLV S Pseudotypes
Retroviral particles pseudotyped with SARS-CoV S
were made by cotransfection of an S-expressing plasmid,
pCAGGS-S, with plasmids encoding MLV or HIV gag-pol
and GFP vector genome in 293T cells. Culture super-
natants were used to infect human TE671, 293T, and quail
QT6/ACE2 cell lines. VSV-G pseudotyped MLV particles,
MLV(VSV), and HIV particles, HIV(VSV), were used as
controls. MLV(VSV) and HIV(VSV) pseudotypes infected
all 3 cell lines tested. MLV(SARS) and HIV(SARS)
pseudotypes infected 293T (which have a low level of
endogenous ACE2 expression) and QT6/ACE2 but not
TE671 cells (Figure 1). The highest titer (3.5 + 105 IU/mL)
was obtained with the combination of QT6/ACE2 cells and
MLV(SARS), so this system was employed for all subse-
quent assays.
Validation of Pseudotype Microneutralization Assay
A blinded panel of 50 samples comprising sera from
healthy persons, patients infected with other human coron-
aviruses (OC43 and 229E), patients infected with influenza
RESEARCH
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virus, and persons who were convalescent from SARS was
provided by the Health Protection Agency (HPA), United
Kingdom, for the validation of our pseudotype neutraliza-
tion assay. For 12 samples positive for both assays, 90%
and 50% inhibitory concentration (IC90 and IC50) pseudo-
type neutralizing titers were compared with titers obtained
at HPA by neutralization assay using replication-compe-
tent SARS-CoV. Logarithmic plots of pseudotype versus
live virus neutralization titers are shown in Figure 2.
Correlation coefficients for pseudotype IC90 and IC50 titers
versus live SARS-CoV neutralization titers were 0.69 and
0.78, respectively. MLV(SARS) entry into QT6/ACE2
cells was not substantially inhibited by sera from healthy
persons or from persons with human coronavirus OC43
and 229E antibodies. MLV(VSV) infection was not inhib-
ited by any sera (data not shown). The pseudotype assay
was thus shown to be both sensitive and specific for
SARS-CoV neutralizing antibodies, with no evidence for
cross-reaction with the other human coronaviruses.
Although the live virus assay was based on the Frankfurt
SARS-CoV isolate, and the pseudotype assay was based
on the Urbani isolate, they gave equivalent titers, including
analysis of serum from the person from whom the
Frankfurt isolate was made.
Neutralizing Antibody Response to SARS-CoV S
Blood samples from the Hong Kong cohort of patients
were tested for neutralizing antibodies to the SARS-CoV S
protein by using the pseudotype neutralization assay.
Figure 3 shows the number of patients positive for neutral-
izing antibodies and the mean neutralizing antibody titer
displayed by week after onset of fever. Samples taken dur-
ing the convalescent and recovered phase (after day 28 fol-
lowing onset of fever) are grouped into longer time blocks
(29–100 days, 101–200 days, and >201 days). In the first
week after onset of fever, all patient samples tested were
negative for neutralizing antibody. Appearance of neutral-
izing antibody was first seen in week 2 with 9 (64%) of 14
patients becoming positive. Geometric mean IC90 neutral-
izing antibody titers ranged from negative (<10) to 40. In
week 3, all patients were positive for neutralizing antibod-
ies with titers from 10 to 200. IC90 titers peaked during
week 4 (mean titers 28–640) but persisted in some patients
for >200 days after onset of fever. Figure 4 shows the lon-
gitudinal profiles of neutralizing antibody responses to
SARS-CoV S in 4 representative patients for whom serial-
ly collected blood samples were available for testing. 
Discussion
We have developed a retroviral pseudotype-based assay
that facilitates the accurate determination of neutralizing
antibody responses to SARS-CoV without the use of repli-
cation-competent virus. Since the neutralization titers
measured on replication-competent SARS-CoV and
pseudotypes are highly correlated, this assay can be wide-
ly applied in routine diagnostics and used for the preclini-
cal evaluation of candidate vaccines and immune therapies
for SARS, without the pathogen itself being handled. This
advantage is important because nosocomial infections
have arisen from laboratory handling of SARS-CoV in
Taiwan, Singapore, and Beijing (37). A lack of good, quan-
titative assays for SARS-CoV replication in vitro also
Neutralizing Antibody Response to SARS Coronavirus
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Figure 1. Infectivity of retroviral severe acute respiratory syn-
drome–associated coronavirus (SARS-CoV) spike protein (S)
pseudotypes on target cells. SARS-CoV S-mediated infection of
human 293T, TE671, and quail QT6/ACE2 was assessed. Murine
leukemia virus (MLV) or HIV pseudotypes bearing either the
pantropic vesicular stomatitis virus envelope protein (VSV-G) as a
positive control, or the SARS-CoV S, were added to target cells.
After 72 h, green fluorescent protein (GFP)–positive cells were
counted by fluorescence-activated cell sorter analysis. Infection
titers are given as infectious units per milliliter (IU/mL). Arrow indi-
cates that infection titer was less than the detection limit, 102 IU/mL.
Figure 2. Correlation of neutralizing antibody titers measured by
plaque reduction assay with titers measured with pseudotype
assay. LV, neutralizing antibody titer by using replication-compe-
tent severe acute respiratory syndrome-associated coronavirus
(SARS-CoV) (live virus); PV, neutralizing antibody titer by using
pseudotype virus; PV90 (filled black diamonds), 90% neutralizing
antibody titer by using murine leukemia virus (MLV) (SARS)
pseudotype virus; PV50 (open squares), 50% neutralizing antibody
titer. Logarithmic trendlines were fitted to the data by using
Microsoft Excel 2003 (Microsoft Corp., Redmond, WA, USA).
Correlation coefficients for LV versus PV90 and LV versus PV50 are
0.69 and 0.78, respectively.
makes the pseudotype assay, with its easily interchange-
able reporter genes, a more flexible platform with which to
study neutralization and cell tropism.
Our assay detected neutralizing antibodies generated
during both the acute and convalescent phases of SARS
infection. When looking for neutralizing antibody respons-
es, previous researchers have predominantly tested sam-
ples taken during the convalescent phase of the disease,
whereas we found that during the period 8–14 days after
onset of fever, 9 patients in our cohort had neutralizing
responses to SARS S protein. Viral load, as measured by
real-time RT-PCR, for 19 of the patients in our cohort, was
previously shown to peak at approximately day 4 or 5 after
onset of fever and then decreased to barely detectable
around the time of seroconversion (38), which suggests
that the neutralizing antibody response may play a role in
viral clearance. This finding has implications for diagnos-
tics and surveillance, since positive diagnoses for neutral-
izing antibodies can be made earlier in infection and as a
complement to testing for IgG responses by enzyme-
linked immunosorbent assay. SARS has yet to manifest
itself as a seasonal epidemic threat like influenza, which
makes mass vaccination an unlikely scenario. The rapid
detection of neutralizing antibodies seen in this study sug-
gests that localized vaccination with an effective vaccine is
likely to help control the spread of SARS-CoV during an
outbreak, if vaccine elicits as rapid a response as live virus.
This article also reports longitudinal neutralizing anti-
body profiles in patients with SARS by using blood sam-
ples collected at serial time points (up to day 287). A broad
spectrum of longitudinal profiles is seen in patients, and
neutralizing antibody levels persist in many recovered per-
sons for several months (Figure 4). In only 1 patient did we
find a complete loss of neutralizing antibody titer after a
sharp rise, which began at the end of the acute phase (day
10). In a second patient, IC90 neutralizing antibody titers
attained 640 by day 22 after onset of fever, followed by a
decline; however, in another patient, neutralizing antibody
was detectable at day 261 after onset of fever. Maintenance
of neutralizing antibody titers will have important implica-
tions for vaccine design.
Gao et al. (39) tested in rhesus macaques an adenoviral
vaccine that was made up of the S1 spike fragment, M, and
N; the test showed that strong neutralizing antibody
responses were generated, some of which appeared early
after vaccination. We have shown that some patients con-
valescing from SARS have similar responses before full
recovery, which suggests that this level of vaccine-induced
neutralizing antibodies may be protective. Initial preclini-
cal studies in mice and hamsters are encouraging and show
that neutralizing antibodies are sufficient to protect against
live virus challenge (16–19,40). Candidate vaccines for
SARS must be moved from the preclinical evaluation
phase to clinical trials in human volunteers as rapidly as
possible, since the possibility of further SARS outbreaks is
uncertain. The method used here to analyze natural infec-
tion can be applied to clinical trials of candidate vaccines,
and we expect this test to be equally applicable to animal
sera.
Acknowledgments
We are grateful to Greg Towers, Laura Ylinen and Hoe N.
Leong for reagents and advice.
This study was supported by the Wellcome Trust, Medical
Research Council, and Health Protection Agency.
Dr. Temperton is a postdoctoral research fellow at the Wohl
Virion Centre, Division of Infection and Immunity, University
College London, United Kingdom. His research interests include
viral pseudotypes, viral neutralization studies, and vaccines.
RESEARCH
414 Emerging Infectious Diseases •  www.cdc.gov/eid •  Vol. 11, No. 3, March 2005
Figure 3. Severe acute respiratory syndrome-associated coron-
avirus (SARS-CoV) neutralizing antibody-positive rate by time of
blood sample collection (days after onset of fever). Black bars rep-
resent the number of patients tested for neutralizing antibodies
(Nab). White bars represent the number of patients whose
assayed samples were positive for neutralizing antibodies (Nab+).
Samples are considered positive for Nab if the 90% neutralizing
antibody titer determined by using murine leukemia virus (MLV)
(SARS) pseudotypes is >10. Line plot with open white circles
shows the geometric mean (GM) Nab titer within each time frame.
IC90, 90% inhibitory concentration.
Figure 4. Neutralizing antibodies to severe acute respiratory syn-
drome-associated coronavirus spike protein in sequential blood
samples from 4 representative patients. Lines represent profiles of
individual patients. Filled black symbols represent geometric mean
titers at individual time points. IC90, 90% inhibitory concentration.
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